Penn Pharmaceutical Services Ltd, a leading provider of integrated pharmaceutical development, clinical trial supply and custom manufacturing services to the international healthcare industry has expanded its clinical trial supplies distribution capabilities seven-fold with the opening of a new 75,000 sq. ft., state-of-the art temperature controlled storage and distribution facility in South Wales, UK.

The new facility has 2,400 pallet locations making it one of the EU’s largest facilities with regulatory approval for the storage and distribution of investigational medicinal products (IMPs) and commercial pharmaceuticals. The new facility further compliments Penn’s already existing network of global distribution hubs and cold chain supply which enable’s clients to reduce time and costs when running clinical trials in a variety of countries simultaneously.

John Roberts, Commercial and Manufacturing Director of Penn Pharmaceutical Services UK, said, "The opening of our new storage and distribution facility in the UK means that we ideally are placed geographically to support our EU and non-EU clients in the storage, distribution and inventory management of their clinical trial supplies.

Penn has been helping pharma and biotech companies of all sizes for over 28 years to expedite their product from clinic to market, fast, efficiently and cost effectively. Penn has seen phenomenal growth over the last couple of years and in response to growing market and customer needs, this was one of the key areas we felt we could add value to our client’s requirements"

Paul Wituschek, Business Development Director Americas, said, "This investment especially benefits our non-EU clients, particularly the Americas and Japan, as they can use Penn’s storage and distribution services as a "Portal" into the EU marketplace enabling them to import and distribute pharmaceutical products, including IMPs (Investigational Medicinal Products), for use in their clinical trials programmes. Under EU regulations all clinical trial and some commercial products that are being used in EU clinical trials must be first QP released before they can be sent to clinical trial sites. Penn has six dedicated QPs on site who are all experts in EU regulatory procedures.

With all of Penn’s drug development, clinical trial manufacturing, labelling and packing, storage and distribution supply, manufacturing and support services all based at the same site, our customer can experience a truly integrated, personal service".

Penn has global reach through an international sales force and strategic alliances for its services offered from its single site operation in South Wales, UK. It is a leading Welsh company that provides a range of fully integrated and cost effective pharmaceutical development, clinical trial supply and custom manufacturing services to the international health care industry.

Penn’s expertise and unique range of services are designed to support pharmaceutical and biotech companies across the world with drugs in development and help them progress these from initial development through clinical trials to the market.

To discuss how we can support your drug development and clinical trial programmes contact your local Business Development Director :

UK/Europe/ROW: Rob Jones Rob.Jones@pennpharm.com

Americas: Paul Wituschek Paul.Wituschek@pennpharm.com